Multi-omics reveals PCSK9 induces precursor-like macrophage M2 polarization to exacerbate immunosuppression in peritoneal metastasis
Journal for ImmunoTherapy of Cancer · 2026-11 · 14 (11) · e016573
DOI: 10.1136/jitc-2026-016573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.11.2026. Verfasst von Zhihui Xi und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou, Guangdong, China. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Special Support Program, China Postdoctoral Science Foundation, the Key Technology and Application Project of Pressurized Intraperitoneal Aerosol Chemotherapy.
Abstract (Originalsprache)
Background
Peritoneal metastasis (PM) is characterized by an immunosuppressive tumor microenvironment (TME), therapeutic resistance, and poor clinical outcomes. However, the key mediators driving immune suppression in PM remain largely unknown. This study aimed to identify the central regulators of the immunosuppressive TME and evaluate their therapeutic potential.
Methods
Integrated analyses were performed using single-cell RNA sequencing data from 19 clinical samples together with multiple bulk RNA-seq datasets to characterize the immune landscape of PM. Mechanistic studies were conducted to investigate the role of tumor-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) in macrophage polarization and T-cell function. The therapeutic effects of PCSK9 inhibition, alone or in combination with anti- programmed cell death protein 1 (PD-1) therapy following chemotherapy, were evaluated in preclinical models. In addition, the efficacy of anti-PCSK9 therapy delivered via pressurized intraperitoneal aerosol chemotherapy (PIPAC) was validated in a rabbit model.
Results
Integrated transcriptomic analyses identified precursor-like macrophage M2 polarization as a central driver of the immunosuppressive TME in PM. Mechanistically, tumor-derived PCSK9 promoted M2 polarization of precursor-like macrophages through the nuclear factor kappa-B (NF-κB)-interleukin-10 (IL-10) signaling axis, leading to impaired T-cell function. PCSK9 inhibition reversed macrophage polarization and reprogrammed the TME toward an antitumor phenotype by enhancing T-cell activation and recruitment via the Cxcl16-Cxcr6 axis. In our exploratory preclinical experiments, sequential chemotherapy followed by combined anti-PCSK9 and anti-PD-1 therapy demonstrated schedule-dependent therapeutic benefit. Furthermore, anti-PCSK9 therapy delivered through PIPAC showed therapeutic efficacy in a rabbit model.
Conclusions
PCSK9 is a key mediator of immune suppression in PM by promoting immunosuppressive macrophage polarization and T-cell dysfunction. Targeting PCSK9 remodels the TME and enhances antitumor immunity, supporting PCSK9 inhibition as a promising therapeutic strategy, particularly in combination with chemotherapy and immune checkpoint blockade for the treatment of PM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
- Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangzhou, Guangdong, China.
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
- Department of Gastrointestinal Surgery, Department of General Surgery, Xiangyang Central Hospital, Xiangyang, Hubei, China.
- Department of Gastrointestinal Surgery, Department of General Surgery, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangzhou, Guangdong, China fenghuolun2022@qq.com liyong@gdph.org.…
- School of Medicine, South China University of Technology, Guangzhou, Guangdong, China fenghuolun2022@qq.com liyong@gdph.org.cn lirenjie@gdph.org.cn.
Förderung
- Guangdong Special Support Program
- China Postdoctoral Science Foundation
- the Key Technology and Application Project of Pressurized Intraperitoneal Aerosol Chemotherapy
- National Natural Science Foundation of China
- Ganzhou Science and Technology Project
Zitieren
APA
Xi, Z., Guo, X., Zhang, Y., Xing, Y., Fan, Q., Zhou, J., Chen, X., Chen, K., Xia, B., Zhang, Y., Li, R., Feng, H., & Li, Y. (2026). Multi-omics reveals PCSK9 induces precursor-like macrophage M2 polarization to exacerbate immunosuppression in peritoneal metastasis. Journal for ImmunoTherapy of Cancer, 14(11), e016573. https://doi.org/10.1136/jitc-2026-016573
Vancouver
Xi Z, Guo X, Zhang Y, Xing Y, Fan Q, Zhou J, et al. Multi-omics reveals PCSK9 induces precursor-like macrophage M2 polarization to exacerbate immunosuppression in peritoneal metastasis. Journal for ImmunoTherapy of Cancer. 2026;14(11):e016573. doi:10.1136/jitc-2026-016573
BibTeX
@article{Xi2026,
author = {Xi, Zhihui and Guo, Xin and Zhang, Yuhan and Xing, Yiheng and Fan, Qiming and Zhou, Jianlong and Chen, Xi and Chen, Kunling and Xia, Baijin and Zhang, Yuyuan and Li, Renjie and Feng, Huolun and Li, Yong},
title = {Multi-omics reveals PCSK9 induces precursor-like macrophage M2 polarization to exacerbate immunosuppression in peritoneal metastasis},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {11},
pages = {e016573},
doi = {10.1136/jitc-2026-016573}
}
EUVIMED